Previous close | 0.5000 |
Open | 0.6200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 330.00 |
Expiry date | 2025-01-17 |
Day's range | 0.5000 - 0.6200 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.